A careful evaluation of the therapeutic choice is necessary in every phase of diabetes progression
Una scelta terapeutica consapevole è necessaria in ogni fase della malattia
National and international diabetes guidelines recommend achieving a target value of glycated hemoglobin value that is dependent upon various factors including patient age, disease duration, co-morbidities, life expectancy and socio-economic conditions. The drug of choice is usually metformin, which can be associated with different classes of oral and injective drugs including insulin, in order to optimize the glycemic balance with the lowest possible risk of hypoglycemic episodes. The clinical case we report shows how a correct therapeutic choice, specifically with linagliptin, can reach a good glycemic control even in elderly subjects, suffering from diabetes mellitus for many years, starting from a severe metabolic imbalance after a multi-year therapy with sulphonylureas (Diabetology).
Copyright (c) 2018 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.